221 related articles for article (PubMed ID: 38319162)
1. Brain Tumor Imaging without Gadolinium-based Contrast Agents: Feasible or Fantasy?
Wamelink IJHG; Azizova A; Booth TC; Mutsaerts HJMM; Ogunleye A; Mankad K; Petr J; Barkhof F; Keil VC
Radiology; 2024 Feb; 310(2):e230793. PubMed ID: 38319162
[TBL] [Abstract][Full Text] [Related]
2. Noncontrast T2-Weighted Magnetic Resonance Imaging Sequences for Long-Term Monitoring of Asymptomatic Convexity Meningiomas.
He JQ; Iv M; Li G; Zhang M; Hayden Gephart M
World Neurosurg; 2020 Mar; 135():e100-e105. PubMed ID: 31734418
[TBL] [Abstract][Full Text] [Related]
3. Gadolinium retention in gliomas and adjacent normal brain tissue: association with tumor contrast enhancement and linear/macrocyclic agents.
Kiviniemi A; Gardberg M; Ek P; Frantzén J; Bobacka J; Minn H
Neuroradiology; 2019 May; 61(5):535-544. PubMed ID: 30710184
[TBL] [Abstract][Full Text] [Related]
4. Can Virtual Contrast Enhancement in Brain MRI Replace Gadolinium?: A Feasibility Study.
Kleesiek J; Morshuis JN; Isensee F; Deike-Hofmann K; Paech D; Kickingereder P; Köthe U; Rother C; Forsting M; Wick W; Bendszus M; Schlemmer HP; Radbruch A
Invest Radiol; 2019 Oct; 54(10):653-660. PubMed ID: 31261293
[TBL] [Abstract][Full Text] [Related]
5. Contrast-to-Dose Relationship of Gadopiclenol, an MRI Macrocyclic Gadolinium-based Contrast Agent, Compared with Gadoterate, Gadobenate, and Gadobutrol in a Rat Brain Tumor Model.
Robert P; Vives V; Grindel AL; Kremer S; Bierry G; Louin G; Ballet S; Corot C
Radiology; 2020 Jan; 294(1):117-126. PubMed ID: 31660804
[TBL] [Abstract][Full Text] [Related]
6. Signal Increase on Unenhanced T1-Weighted Images in the Rat Brain After Repeated, Extended Doses of Gadolinium-Based Contrast Agents: Comparison of Linear and Macrocyclic Agents.
Jost G; Lenhard DC; Sieber MA; Lohrke J; Frenzel T; Pietsch H
Invest Radiol; 2016 Feb; 51(2):83-9. PubMed ID: 26606548
[TBL] [Abstract][Full Text] [Related]
7. Dynamic susceptibility contrast and dynamic contrast-enhanced MRI characteristics to distinguish microcystic meningiomas from traditional Grade I meningiomas and high-grade gliomas.
Hussain NS; Moisi MD; Keogh B; McCullough BJ; Rostad S; Newell D; Gwinn R; Foltz G; Mayberg M; Aguedan B; Good V; Fouke SJ
J Neurosurg; 2017 Apr; 126(4):1220-1226. PubMed ID: 27285539
[TBL] [Abstract][Full Text] [Related]
8. Gadolinium Deposition in the Brain: A Systematic Review of Existing Guidelines and Policy Statement Issued by the Canadian Association of Radiologists.
Costa AF; van der Pol CB; Maralani PJ; McInnes MDF; Shewchuk JR; Verma R; Hurrell C; Schieda N
Can Assoc Radiol J; 2018 Nov; 69(4):373-382. PubMed ID: 30249408
[TBL] [Abstract][Full Text] [Related]
9. Deep-learning-based synthesis of post-contrast T1-weighted MRI for tumour response assessment in neuro-oncology: a multicentre, retrospective cohort study.
Jayachandran Preetha C; Meredig H; Brugnara G; Mahmutoglu MA; Foltyn M; Isensee F; Kessler T; Pflüger I; Schell M; Neuberger U; Petersen J; Wick A; Heiland S; Debus J; Platten M; Idbaih A; Brandes AA; Winkler F; van den Bent MJ; Nabors B; Stupp R; Maier-Hein KH; Gorlia T; Tonn JC; Weller M; Wick W; Bendszus M; Vollmuth P
Lancet Digit Health; 2021 Dec; 3(12):e784-e794. PubMed ID: 34688602
[TBL] [Abstract][Full Text] [Related]
10. Gadolinium Brain Deposition after Macrocyclic Gadolinium Administration: A Pediatric Case-Control Study.
Tibussek D; Rademacher C; Caspers J; Turowski B; Schaper J; Antoch G; Klee D
Radiology; 2017 Oct; 285(1):223-230. PubMed ID: 28640695
[TBL] [Abstract][Full Text] [Related]
11. Use of gadolinium-based contrast agents in multiple sclerosis: a review by the ESMRMB-GREC and ESNR Multiple Sclerosis Working Group.
Rovira À; Doniselli FM; Auger C; Haider L; Hodel J; Severino M; Wattjes MP; van der Molen AJ; Jasperse B; Mallio CA; Yousry T; Quattrocchi CC;
Eur Radiol; 2024 Mar; 34(3):1726-1735. PubMed ID: 37658891
[TBL] [Abstract][Full Text] [Related]
12. Quantitative assessment of gadolinium deposition in dentate nucleus using quantitative susceptibility mapping.
Hinoda T; Fushimi Y; Okada T; Arakawa Y; Liu C; Yamamoto A; Okada T; Yoshida K; Miyamoto S; Togashi K
J Magn Reson Imaging; 2017 May; 45(5):1352-1358. PubMed ID: 27664936
[TBL] [Abstract][Full Text] [Related]
13. Gadolinium-Based Contrast Agents in Kidney Disease: Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists.
Schieda N; Blaichman JI; Costa AF; Glikstein R; Hurrell C; James M; Jabehdar Maralani P; Shabana W; Tang A; Tsampalieros A; van der Pol C; Hiremath S
Can Assoc Radiol J; 2018 May; 69(2):136-150. PubMed ID: 29706252
[TBL] [Abstract][Full Text] [Related]
14. High Signal Intensity in Dentate Nucleus on Unenhanced T1-weighted MR Images: Association with Linear versus Macrocyclic Gadolinium Chelate Administration.
Kanda T; Osawa M; Oba H; Toyoda K; Kotoku J; Haruyama T; Takeshita K; Furui S
Radiology; 2015 Jun; 275(3):803-9. PubMed ID: 25633504
[TBL] [Abstract][Full Text] [Related]
15. Linear gadolinium-based contrast agent (gadodiamide and gadopentetate dimeglumine)-induced high signal intensity on unenhanced T
Ichikawa S; Omiya Y; Onishi H; Motosugi U
J Magn Reson Imaging; 2019 Apr; 49(4):1046-1052. PubMed ID: 30307671
[TBL] [Abstract][Full Text] [Related]
16. Risks and Options With Gadolinium-Based Contrast Agents in Patients With CKD: A Review.
Rudnick MR; Wahba IM; Leonberg-Yoo AK; Miskulin D; Litt HI
Am J Kidney Dis; 2021 Apr; 77(4):517-528. PubMed ID: 32861792
[TBL] [Abstract][Full Text] [Related]
17. Effect of at Least 10 Serial Gadobutrol Administrations on Brain Signal Intensity Ratios on T1-Weighted MRI in Children: A Matched Case-Control Study.
Ozturk K; Nascene D
AJR Am J Roentgenol; 2021 Sep; 217(3):753-760. PubMed ID: 33112200
[No Abstract] [Full Text] [Related]
18. Gadolinium is not necessary for surveillance MR imaging in children with chiasmatic-hypothalamic low-grade glioma.
Malbari F; Chintagumpala MM; Wood AC; Levy AS; Su JM; Okcu MF; Lin FY; Lindsay H; Rednam SP; Baxter PA; Paulino AC; Orzaiz GA; Whitehead WE; Dauser R; Supakul N; Kralik SF
Pediatr Blood Cancer; 2021 Oct; 68(10):e29178. PubMed ID: 34133064
[TBL] [Abstract][Full Text] [Related]
19. Gadolinium-based contrast agent attenuation does not impact PET quantification in simultaneous dynamic contrast enhanced breast PET/MR.
Allen TJ; Henze Bancroft LC; Kumar M; Bradshaw TJ; Strigel RM; McMillan AB; Fowler AM
Med Phys; 2022 Aug; 49(8):5206-5215. PubMed ID: 35621727
[TBL] [Abstract][Full Text] [Related]
20. Gadolinium Deposition in Neurology Clinical Practice.
Smith TE; Steven A; Bagert BA
Ochsner J; 2019; 19(1):17-25. PubMed ID: 30983897
[No Abstract] [Full Text] [Related]
[Next] [New Search]
